Related Image: Baltimore LASIK Surgeon Roy Chuck, MD, PhD of the Wilmer Eye Institute at Johns Hopkins Lists with Trusted LASIK Surgeons |
(Date:12/3/2009)HOPKINTON, Mass., Dec. 3 Caliper Life Sciences, Inc. (Nasdaq: CALP ), a leading provider of tools and services for drug discovery and life sciences research, today introduced Living Image 4.0 softwa
(Date:12/2/2009)NEW YORK, Dec. 2 Reportlinker.com announces that a new market research report is available in its catalogue: ,, Carbondioxide Incubators - A Global Market Perspective ,, http://www.reportlinker.co
(Date:12/2/2009)CALGARY, Dec. 2 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc. ("Oncolytics" or the "Company") (TSX:ONC; NASDAQ: ONCY ) announced today that in connection with its previously announced unit offering
(Date:12/2/2009)SINGAPORE, Dec. 2 S*BIO Pte Ltd today announced data presentations on its novel oral JAK2 inhibitor, SB1518, at The American Society of Hematology 51st Annual Meeting and Exposition in New Orleans. ,
Breaking Biology Technology:Caliper Life Sciences Launches Living Image(R) 4.0 Software 2Reportlinker Adds Carbondioxide Incubators - A Global Market Perspective 2Reportlinker Adds Carbondioxide Incubators - A Global Market Perspective 3Reportlinker Adds Carbondioxide Incubators - A Global Market Perspective 4Oncolytics Biotech(R) Inc. Announces Exercise of Underwriters' Over-Allotment Option 2Oncolytics Biotech(R) Inc. Announces Exercise of Underwriters' Over-Allotment Option 3Oncolytics Biotech(R) Inc. Announces Exercise of Underwriters' Over-Allotment Option 4S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders 2S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders 3S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders 4S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders 5...ell Report Identifies SPINK1 as a New Biomarker fo...pendia Bioscience, Inc.,the leading provider of ca...unced the central role of their flagship product O... SPINK1 as a key new therapeutic target and,biomar...rowing compendium of nearly 26,000 gene,expression...
...publication on utility of PRDT,s prion reduction t...utzfeldt-Jakob Disease ("vCJD") from ...ing lunchtime Symposium at meeting to discuss prio... product quality., MONTREAL, Canada and CAMBRIDGE... ProMetic Life Sciences Inc. (TSX:PLI) ("ProMetic"...
... Iris Recognition Algorithm Detects and Compensate...ctions, VILNIUS, Lithuania, June 10 Neurotechnol...ecognition technology to the,company,s suite of bi...elopment products. VeriEye SDK features an advance...and compensates for partial obstructions,irregular...
Other Biology Technology:Oncomine(TM) Again Key to Prostate Cancer Discovery 2ProMetic announces Octapharma publication of PRDT'S prion removal resin in Octaplas(R) manufacturing process at 30th International Congress of the International Society for Blood Transfusion meeting in Macao SAR, China 2ProMetic announces Octapharma publication of PRDT'S prion removal resin in Octaplas(R) manufacturing process at 30th International Congress of the International Society for Blood Transfusion meeting in Macao SAR, China 3ProMetic announces Octapharma publication of PRDT'S prion removal resin in Octaplas(R) manufacturing process at 30th International Congress of the International Society for Blood Transfusion meeting in Macao SAR, China 4ProMetic announces Octapharma publication of PRDT'S prion removal resin in Octaplas(R) manufacturing process at 30th International Congress of the International Society for Blood Transfusion meeting in Macao SAR, China 5ProMetic announces Octapharma publication of PRDT'S prion removal resin in Octaplas(R) manufacturing process at 30th International Congress of the International Society for Blood Transfusion meeting in Macao SAR, China 6New VeriEye SDK from Neurotechnology Enables Development of Reliable, Cost-effective Biometric Iris Recognition Systems 2New VeriEye SDK from Neurotechnology Enables Development of Reliable, Cost-effective Biometric Iris Recognition Systems 3...onal size guidelines for all-terrain vehicles (ATV...ers, according to preliminary results from a study...ased on initial experiments, the researchers found...h match the rider,s age to a recommended vehicle f...hough results are preliminary and the initial expe...
...AM, N.C. By coupling a kicked-up version of micro...rsity scientists are now able to peer so deep into...ting. , If future studies in animal models prove ...pproach can have a wide spectrum of clinical appli...t is removed from the body to assessing the effect...
...w advance in cellular imaging is allowing scientis...he area around tumors, also known as the tumor mic...isease Models & Mechanisms (DMM), dmm.biologists...hods of laser microscopy to track the movement of ... As a tumor grows, it triggers immune responses in...
Other Biology News:Study finds ATV guidelines inadequate 2New technique sees into tissue at greater depth, resolution 2New technique sees into tissue at greater depth, resolution 3...cessory lessens the expensive task of validating m... mass spectrometers. It converts the unprocessed d...quadrupole mass spectrometers into analog format a...ory information management (LIMS) systems for proc...
...were designed for full-length gene cloning and req...ed cDNA clone. The first PCR analysis is performed...ains plasmid DNA from 5,000 clones. Having identif... the reaction products, the second PCR analysis is...
...were designed for full-length gene cloning and req...ed cDNA clone. The first PCR analysis is performed...ains plasmid DNA from 5,000 clones. Having identif... the reaction products, the second PCR analysis is...
...tide Kit, designed for use with Ciphergens Protein... peptides more straightforward and faster than eve...cations - Monitor beta-amyloid expression after dr...ls with disease progression - Evaluate mechanisms ...
Biology Products: